European Union's CHMP Issues Positive Opinion On Sugammadex Schering-Plough Corporation (NYSE: SGP) reported that the Committee for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMEA) has recommended approval of sugammadex for routine reversal of the muscle relaxants rocuronium or vecuronium and for immediate reversal of rocuronium in adults, and for routine reversal following rocuronium in children and adolescents (2-17 years of age).
Source: www.medicalnewstoday.comJazz Pharmaceuticals, Inc. Completes Enrollment In First Of Two Phase III Clinical Trials Of Sodium Oxybate To Treat Fibromyalgia Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced completion of enrollment in the first of two Phase III pivotal clinical trials of JZP-6 (sodium oxybate) for the treatment of fibromyalgia. "Completion of enrollment in this trial is a key milestone in the JZP-6 program. We expect to report top line results from this trial in the fourth quarter of 2008," said Samuel Saks, M.D., Chief Executive Officer.
Source: www.medicalnewstoday.comLabels: No Prescription, Online Pharmacy
# posted by Network @ 5:00 AM
